Advancing the molecular diagnosis of thyroid nodules: Defining benign lesions by molecular profiling

被引:22
作者
Finley, DJ
Lubitz, CC
Wei, C
Zhu, BX
Fahey, TJ
机构
[1] Cornell Univ, Weill Med Coll, Dept Surg, New York, NY USA
[2] Strang Canc Prevent Ctr, New York, NY USA
关键词
D O I
10.1089/thy.2005.15.562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Thyroid nodules are common and most are benign. Previous data from our laboratory and others has suggested that gene profiling can accurately distinguish between benign and malignant thyroid nodules and provide new leads in the study of thyroid tumorigenesis. Current preoperative techniques do not permit distinction between neoplastic and hyperplastic follicular neoplasms. These studies were undertaken to determine whether benign follicular tumors could be subcategorized by molecular profiling. Methods: Molecular profiles of 8 follicular adenomas and 8 hyperplastic nodules were analyzed by oligonucleotide microarray analysis. A list of 402 differentially expressed genes was produced based on a comparison of these two groups. Seven additional benign follicular lesions were then added to the analysis. A hierarchical clustering analysis was performed on all 23 samples, utilizing the gene list generated from the test set, to examine the groups for potential differences and the ability of the gene list to distinguish tumor types. Results: Cluster analysis of all 23 samples produced two distinct groups, one containing the adenomas and one containing the hyperplastic lesions. The analysis was able to identify follicular adenomas with a sensitivity of 84.6% and a specificity of 100%. Conclusions: These data indicate that benign thyroid lesions can be separated into distinct groups through molecular profiling. Analysis of the gene list may help further the understanding of thyroid tumorigenesis. Expression profiling may ultimately allow us to distinguish potentially malignant from benign follicular nodules.
引用
收藏
页码:562 / 568
页数:7
相关论文
共 32 条
[21]   Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas [J].
Marques, AR ;
Espadinha, C ;
Catarino, AL ;
Moniz, S ;
Pereira, T ;
Sobrinho, LG ;
Leite, V .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3947-3952
[22]   HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm [J].
Mase, T ;
Funahashi, H ;
Koshikawa, T ;
Imai, T ;
Nara, Y ;
Tanaka, Y ;
Nakao, A .
ENDOCRINE JOURNAL, 2003, 50 (02) :173-177
[23]   CLONAL COMPOSITION OF BENIGN AND MALIGNANT HUMAN THYROID-TUMORS [J].
NAMBA, H ;
MATSUO, K ;
FAGIN, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (01) :120-125
[24]  
Notterman DA, 2001, CANCER RES, V61, P3124
[25]   The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma [J].
Rosenwald, A ;
Wright, G ;
Chan, WC ;
Connors, JM ;
Campo, E ;
Fisher, RI ;
Gascoyne, RD ;
Muller-Hermelink, HK ;
Smeland, EB ;
Staudt, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (25) :1937-1947
[26]  
Rozen S, 2000, Methods Mol Biol, V132, P365
[27]   Molecular pathogenesis of thyroid cancer [J].
Segev, DL ;
Umbricht, C ;
Zeiger, MA .
SURGICAL ONCOLOGY-OXFORD, 2003, 12 (02) :69-90
[28]   The 'cancer cachectic factor' [J].
Tisdale, MJ .
SUPPORTIVE CARE IN CANCER, 2003, 11 (02) :73-78
[29]   Gene expression profiling predicts clinical outcome of breast cancer [J].
van't Veer, LJ ;
Dai, HY ;
van de Vijver, MJ ;
He, YDD ;
Hart, AAM ;
Mao, M ;
Peterse, HL ;
van der Kooy, K ;
Marton, MJ ;
Witteveen, AT ;
Schreiber, GJ ;
Kerkhoven, RM ;
Roberts, C ;
Linsley, PS ;
Bernards, R ;
Friend, SH .
NATURE, 2002, 415 (6871) :530-536
[30]   NMB, A NOVEL GENE, IS EXPRESSED IN LOW-METASTATIC HUMAN-MELANOMA CELL-LINES AND XENOGRAFTS [J].
WETERMAN, MAJ ;
AJUBI, N ;
VANDINTER, IMR ;
DEGEN, WGJ ;
VANMUIJEN, GNP ;
RUITER, DJ ;
BLOEMERS, HPJ .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (01) :73-81